AIMS Cancer Outcomes Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAdvanced Integrative Medical Science Institute
About this trial
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or
An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;
If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;
If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;
Disqualifiers
Patients not diagnosed with cancer;
Telehealth patients;
Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;
Unwilling to participate in the AIMS Institute observational study.
Trial population
All cancer patients who seek care at AIMS Institute and meet inclusion/exclusion criteria are eligible to participate in this study. Participants will be informed and educated about the prospective outcomes study by clinical staff as part of patient registration and the clinical intake process. Patients may be referred to AIMS Institute by cancer care centers, oncologists and other health care providers, or patients may be self-referred.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
AIM 1 (survival)
Measure DFS and OS in advanced stage cancer patients who receive AIO treatments at AIMS Institute.
Time frame
5 YearsSecondary outcomes
1
AIM 2 (treatment)
Describe AIO treatments prescribed and provided by AIMS physician and their medical staff.
Time frame
5 Years2
AIM 3 (correlate survival with treatment)
Correlate survival outcomes with treatments received.
Time frame
5 YearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov